# EDGAR Filing Document

**Accession Number:** 0001691082
**File Stem:** 0001213900-25-091474
**Filing Date:** 2025-9
**Character Count:** 20101
**Document Hash:** 49d32f612d9fc9c50e33c6aa4b6c0d06
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-091474.hdr.sgml**: 20250925

**ACCESSION NUMBER**: 0001213900-25-091474

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250925

**DATE AS OF CHANGE**: 20250925

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LB PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0001691082
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95235
- **FILM NUMBER:** 251340908

**BUSINESS ADDRESS:**
- **STREET 1:** 575 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 917-450-6581

**MAIL ADDRESS:**
- **STREET 1:** 575 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LB PHARMACEUTICALS INC.
- **DATE OF NAME CHANGE:** 20161129
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pontifax Management 4 G.P. (2015) Ltd.
- **CENTRAL INDEX KEY:** 0001726334

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 14 SHENKAR STREET, BEIT OFEK
- **CITY:** HERZLIYA PITUACH
- **STATE:** L3
- **ZIP:** 46140
- **BUSINESS PHONE:** 972-9-9725617

**MAIL ADDRESS:**
- **STREET 1:** 14 SHENKAR STREET, BEIT OFEK
- **CITY:** HERZLIYA PITUACH
- **STATE:** L3
- **ZIP:** 46140

## Exhibit 99.1

**EXHIBIT 99.1**

**JOINT FILING AGREEMENT** 

The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D with respect to the Ordinary Shares beneficially owned by each of them of LB Pharmaceuticals Inc. This Joint Filing Agreement shall be included as an exhibit to such Schedule 13D.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of the 25 day of September, 2025.

---

| | |
|:---|:---|
| Pontifax VI G.P. L.P. | Pontifax VI G.P. L.P. |
| By: | /s/ Ran Nussbaum |
| Name: | Ran Nussbaum |
| Title: | Managing Partner |
| Pontifax Management 4 G.P. (2015) Ltd. | Pontifax Management 4 G.P. (2015) Ltd. |
| By: | /s/ Ran Nussbaum |
| Name: | Ran Nussbaum |
| Title: | Managing Partner |
| Ran Nussmabum | Ran Nussmabum |
| /s/ RanNussbaum | /s/ RanNussbaum |
| Tomer Kariv | Tomer Kariv |
| /s/ Tomer Kariv | /s/ Tomer Kariv |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**LB Pharmaceuticals Inc**

*(Name of Issuer)*

**Common Stock, $0.0001 par value per share**

*(Title of Class of Securities)*

**50180M108**

*(CUSIP Number)*

**Asaf Shinar**<br>Pontifax<br>14 Shenkar Street<br>Herzliya Pituach L3 46140<br>972-9-9725617

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**09/12/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **50180M108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Pontifax Management 4 G.P. (2015) Ltd.** | Name of reporting person<br>**Pontifax Management 4 G.P. (2015) Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1411681.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1411681.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1411681.00** | Aggregate amount beneficially owned by each reporting person<br>**1411681.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.3%** | Percent of class represented by amount in Row (11)<br>**6.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** 1. Includes (i) 898,201 Ordinary Shares held by Pontifax (Israel) VI Limited Partnership and (ii) 513,480 Ordinary Shares held by Pontifax (Cayman) VI Limited Partnership. Pontifax VI G.P. L.P. is the general partner of each of Pontifax (Israel) VI Limited Partnership and Pontifax (Cayman) VI Limited Partnership. Pontifax Management 4 G.P. (2015) Ltd. is the general partner of Pontifax VI G.P. L.P.

2. Based on 22,442,989 shares of Common Stock outstanding as of September 10, 2025, as provided for in LB Pharmaceuticals Inc.'s prospectus filed with the Securities and Exchange Commission ("SEC") on September 12, 2025.

| **CUSIP No.** | **50180M108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Pontifax VI G.P. L.P.** | Name of reporting person<br>**Pontifax VI G.P. L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1411681.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1411681.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1411681.00** | Aggregate amount beneficially owned by each reporting person<br>**1411681.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.3%** | Percent of class represented by amount in Row (11)<br>**6.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** 1. Includes (i) 898,201 Ordinary Shares held by Pontifax (Israel) VI Limited Partnership and (ii) 513,480 Ordinary Shares held by Pontifax (Cayman) VI Limited Partnership. Pontifax VI G.P. L.P. is the general partner of each of Pontifax (Israel) VI Limited Partnership and Pontifax (Cayman) VI Limited Partnership.

2. Based on 22,442,989 shares of Common Stock outstanding as of September 10, 2025, as provided for in LB Pharmaceuticals Inc.'s prospectus filed with the SEC on September 12, 2025.

| **CUSIP No.** | **50180M108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ran Nussbaum** | Name of reporting person<br>**Ran Nussbaum** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1411681.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1411681.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1411681.00** | Aggregate amount beneficially owned by each reporting person<br>**1411681.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.3%** | Percent of class represented by amount in Row (11)<br>**6.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** 1. Includes (i) 898,201 Ordinary Shares held by Pontifax (Israel) VI Limited Partnership and (ii) 513,480 Ordinary Shares held by Pontifax (Cayman) VI Limited Partnership. Pontifax VI G.P. L.P. is the general partner of each of Pontifax (Israel) VI Limited Partnership and Pontifax (Cayman) VI Limited Partnership. Pontifax Management 4 G.P. (2015) Ltd. is the general partner of Pontifax VI G.P. L.P. Tomer Kariv and Ran Nussbaum are the Managing Partners of Pontifax Management 4 G.P. (2015) Ltd. and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax entities listed above.

2. Based on 22,442,989 shares of Common Stock outstanding as of September 10, 2025, as provided for in LB Pharmaceuticals Inc.'s prospectus filed with the SEC on September 12, 2025.

| **CUSIP No.** | **50180M108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Tomer Kariv** | Name of reporting person<br>**Tomer Kariv** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1411681.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1411681.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1411681.00** | Aggregate amount beneficially owned by each reporting person<br>**1411681.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.3%** | Percent of class represented by amount in Row (11)<br>**6.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** 1. Includes (i) 898,201 Ordinary Shares held by Pontifax (Israel) VI Limited Partnership and (ii) 513,480 Ordinary Shares held by Pontifax (Cayman) VI Limited Partnership. Pontifax VI G.P. L.P. is the general partner of each of Pontifax (Israel) VI Limited Partnership and Pontifax (Cayman) VI Limited Partnership. Pontifax Management 4 G.P. (2015) Ltd. is the general partner of Pontifax VI G.P. L.P. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management 4 G.P. (2015) Ltd. and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax entities listed above.

2. Based on 22,442,989 shares of Common Stock outstanding as of September 10, 2025, as provided for in LB Pharmaceuticals Inc.'s prospectus filed with the SEC on September 12, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**(b) Name of Issuer:**
LB Pharmaceuticals Inc

**(c) Address of Issuer's Principal Executive Offices:**
One Pennsylvania Plaza,, Suite 1025, New York, NY, 10119

**Item 4. Purpose of Transaction**

The Reporting Persons acquired the securities reported herein for investment purposes, subject to the following:

 The Reporting Persons intend to review on a continuing basis the investments in the Issuer by the Reporting Persons. The Reporting Persons may engage in discussions with management, the board of directors of the Issuer (the "Board"), other shareholders of the Issuer and other relevant parties concerning the Reporting Persons' investment in the Issuer's securities. Depending on various factors, including, without limitation, the price and availability of the Issuer's securities, subsequent developments affecting the Issuer, the Issuer's business and the Issuer's prospects, other investment and business opportunities available to such Reporting Persons, general industry and economic conditions, the securities markets in general, tax considerations and other factors deemed relevant by such Reporting Persons, the Reporting Persons may seek to sell or otherwise dispose some or all of the Issuer's securities or any derivatives thereof (which may include distributing some or all of such securities to such Reporting Person's respective partners or beneficiaries, as applicable) from time to time, and/or may seek to acquire additional securities of the Issuer or any derivatives thereof (which may include rights or securities exercisable or convertible into securities of the Issuer) from time to time, in each case, in open market or private transactions, block sales or otherwise.

Ran Nussbaum, a Managing Director at Pontifax Management or one of its affiliates, serves as a member of the Board and, in such capacity, may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

Except as described in this Schedule 13D, the Reporting Person does not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, the Reporting Person, at any time and from time to time, may review, reconsider and change their position and/or purpose and/or develop such plans.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5.

Calculation of the percentage of shares of Common Stock beneficially owned by each Reporting Person is based on 22,442,989 shares of Common Stock outstanding following the Issuer's IPO based on information set forth in the Issuer's prospectus filed with the SEC on September 12, 2025.

The aggregate number and percentage of Common Shares beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on rows 7 through 11 and row 13 of the cover pages of this Schedule 13D and are incorporated herein by reference.

Pontifax (Israel) and Pontifax (Cayman) directly hold 898,201 and 513,480 shares of the Common Stock, respectively. The Managing Partners of Pontifax Management, the general partner of Pontifax VI G.P. L.P., which, in turn, is the general partner of both Pontifax (Israel) and Pontifax (Cayman), are Messrs. Tomer Kariv and Ran Nussbaum.

**(b)**
See Item 5(a) above.

**(c)**
Except as set forth in this Schedule 13D, none of the Reporting Persons has effected any transaction in Common Stock in the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Except for the matters described herein, the Reporting Persons have no contract, arrangement, understanding or relationship (legal or otherwise) among the Reporting Persons or between the Reporting Persons and any other person with respect to the securities of the Issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Pontifax Management 4 G.P. (2015) Ltd.

**Signature:** /s/ Ran Nussbaum

**Name/Title:** Ran Nussbaum Managing Partner

**Date:** 09/25/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Pontifax VI G.P. L.P.

**Signature:** /s/ Ran Nussmabum

**Name/Title:** Ran Nussbaum Managing Partner

**Date:** 09/25/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ran Nussbaum

**Signature:** /s/ Ran Nussbaum

**Name/Title:** Ran Nussbaum

**Date:** 09/25/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Tomer Kariv

**Signature:** /s/ Tomer Kariv

**Name/Title:** Tomer Kariv

**Date:** 09/25/2025